DSM Announces Patent Grants for Proprietary XD Biomanufacturing Technology

DSM Pharmaceutical Products has announced that several countries have granted patents or have given statements of patent allowance to its proprietary XD? high cell density process technology.

DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM N.V., has announced that several countries have granted patents or have given statements of patent allowance to its proprietary XD? high cell density process technology.

DSM Biologics focuses on optimizing biopharmaceutical manufacturing through its unique set of technologies. The XD? technology is an important building block in DSM's vision for the future of biopharmaceutical manufacturing. This technology is a highly intensified cell culture process with titer achievement 5-to-15 times higher compared to current standard biomanufacturing processes.  It is widely applicable for multiple products including proteins, fusion proteins and antibodies, and has been successfully employed across the full spectrum of mammalian cell systems. XD? has also shown impressive results